BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38212074)

  • 21. [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy].
    Maurer T; Gesterkamp H; Nguyen N; Westenfelder K; Gschwend JE; Budäus L; Rauscher I; Vag T; Weber W; Eiber M
    Aktuelle Urol; 2021 Apr; 52(2):143-148. PubMed ID: 32854128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of
    Li Y; Han D; Wu P; Ren J; Ma S; Zhang J; Song W; Lin X; Jiao D; Shi S; Yang F; Wu J; Meng P; Wen W; Kang F; Wang J; Qin W
    Sci Rep; 2020 Jul; 10(1):10963. PubMed ID: 32620790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
    Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
    Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
    BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraindividual Comparison of
    Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
    J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
    [No Abstract]   [Full Text] [Related]  

  • 27. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 28. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
    Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L
    Eur Urol Oncol; 2024 Jun; 7(3):544-552. PubMed ID: 38061976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
    BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.
    Scobioala S; Kittel C; Wolters H; Huss S; Elsayad K; Seifert R; Stegger L; Weckesser M; Haverkamp U; Eich HT; Rahbar K
    Ann Nucl Med; 2021 May; 35(5):628-638. PubMed ID: 33742373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Performance of
    Margel D; Bernstine H; Groshar D; Ber Y; Nezrit O; Segal N; Yakimov M; Baniel J; Domachevsky L
    Radiology; 2021 Nov; 301(2):379-386. PubMed ID: 34463555
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
    Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Update on the Role of mpMRI and
    Bagheri H; Mahdavi SR; Geramifar P; Neshasteh-Riz A; Sajadi Rad M; Dadgar H; Arabi H; Zaidi H
    Clin Genitourin Cancer; 2024 Jun; 22(3):102076. PubMed ID: 38593599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between
    Frumer M; Milk N; Rinott Mizrahi G; Bistritzky S; Sternberg I; Leibovitch I; Dekel Y; Amiel GE; Zisman A; Baniel J; Haifler M; Gal J; Hoffman A; Sagy I; Rosenzweig B; Haramaty R; Golan S
    Abdom Radiol (NY); 2020 Dec; 45(12):4194-4201. PubMed ID: 32671440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.